Pulse Biosciences realigns to accelerate AFib catheter program after strong clinical data

PULSE BIOSCIENCES, INC.

100% acute success at 6 months (75/75 patients); 96% durable PVI at 12 months (45/47).
Reducing headcount in sales/marketing; redirecting resources to cardiac catheter program and pivotal IDE study.
Streamlining soft-tissue ablation to focus on benign thyroid nodules and real-world data.
Late-breaking 12-month follow-up data to be presented at Heart Rhythm 2026 on April 25.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.